Molecular biology and cytopathology: Principles and applications;Cytopathologie moléculaire: Outils et applications

Annales de Pathologie

Volumn 32, Issue 6, 2012, Pages 444-450

  Vielh, Philippe ^a   Schmitt, Fernando Carlos ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b University of Porto   (Portugal)

Author keywords

Cytopathology; Molecular biology

Indexed keywords

CYTOLOGY; CYTOPATHOLOGY; HUMAN; MOLECULAR BIOLOGY; NEEDLE BIOPSY; NEOPLASM; SHORT SURVEY;

EID: 84871006953     PISSN: 02426498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annpat.2012.09.209     Document Type: Short Survey

References (39)

1. Schmitt F.C., Longatto-Filho A., Valent A., Vielh P. Molecular techniques in cytopathology practice. J Clin Pathol 2008, 61:258-267.
2. Schmitt F.C., Barroca H. Possible use and role of molecular techniques in fine needle aspiration. Diagn Histopathol 2011, 17:286-292.
3. Schmitt F., Barroca H. Role of ancillary studies in fine-needle aspiration from selected tumors. Cancer Cytopathol 2012, 120:145-160.
4. Di Lorito A., Schmitt F.C. Cytopathology and sequencing: next (or last) generation?. Diagn Cytopathol 2012, 40:459-461.
5. Schmitt F.C. Molecular cytopathology and flow cytometry: pre-analytical procedures matter. Cytopathology 2011, 22:355-357.
6. Pang N.K.B., Nga M.E., Chin S.Y., Ismail T.M., Lim G.L., Soong R., et al. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma. Cytopathology 2011, 22:358-364.
7. Colasacco C., Mount S., Leiman G. Documentation of immunocytochemistry controls in the cytopathologic literature: a meta-analysis of 100 journal articles. Diagn Cytopathol 2011, 39:245-250.
8. Longatto-Filho A., Gonçalves A.E., Martinho O., Schmitt F.C., Reis R.M. Liquid-based cytology in DNA-based molecular research. Anal Quant Cytol Histol 2009, 31:395-400.
9. Wholschlaeger J., Worm K., Schmitt F., Davidson B., Totsch M. Assessment of DNA, small NCRNA and MRNA detection over time in liquid-based cytology specimens. Cytopathology 2009, 20:67.
10. Motherby H., Nadjari B., Friegel P., Kohaus J., Ramp U., Bocking A. Diagnostic accuracy of effusion cytology. Diagn Cytopathol 1999, 20:350-357.
11. Davidson B., Firat P., Michaels C.W. Serous effusions: etiology, diagnosis and prognosis 2012, Springer-Verlag, London.
12. Reis-Filho J.S., Schmitt F.C. Fluorescence in situ hybridization, comparative genomic hybridization and other molecular biology techniques in the analysis of effusions. Diagn Cytopathol 2005, 33:294-299.
13. Savic S., Franco N., Grilli B., Barascud-Ade V., Herzog M., Bode B., et al. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. Chest 2010, 138:137-144.
14. de Matos Granja N., Soares R., Rocha S., Paredes J., Longatto Filho A., Alves V.A., et al. Evaluation of breast cancer metastases in pleural effusions by molecular biology techniques. Diagn Cytopathol 2002, 27:210-213.
15. Flores-Staino C., Darai-Ramqvist E., Dobra K., Hjerpe A. Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions. Lung Cancer 2010, 68:39-43.
16. Bubendorf L. Multiprobe fluorescence in situ hybridization (Urovysion) for the detection of urothelial carcinoma - FISHing for the right catch. Acta Cytol 2011, 55:113-119.
17. Skacel M., Fahmy M., Brainard J.A., Pettay J.D., Biscotti C.V., Liou L.S., et al. Multitarget fluorescent in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003, 169:2101-2105.
18. Volpe A., Racioppi M., D'Agostino D., Cappa E., Gardi M., Totaro A., et al. Bladder tumor markers: a review of the literature. Int J Biol Markers 2008, 23:249-261.
19. Tabchy A., Valero V., Vidaurre T., Lluch A., Gomez H., Martin M., et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 2010, 16:5351-5361.
20. Amir E., Miller N., Geddie W., Freedman O., Kassam F., Simmons C., et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2011, 30:587-592.
21. Wilking U., Karlsson E., Skoog L., Hatschek T., Lidbrink E., Elmberger G., et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat 2011, 125:553-561.
22. Antonescu C.R. The GIST paradigm: lessons for other kinase-driven cancers. J Pathol 2011, 223:251-261.
23. Gomes A.L., Bardales R.H., Milanezi F., Reis R.M., Schmitt F. Molecular analysis of c-Kit and PDGFRA in GISTs diagnosed by echoendoscopic ultrasound. Am J Clin Pathol 2007, 127:1-8.
24. Lievre A., Bachet J., Boige V., Cayre A., Le Corre D., Buc E., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26:374-379.
25. Oliveira C., Velho S., Moutinho C., Ferreira A., Preto A., Domingo E., et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 2007, 26:158-163.
26. Pitman M.B., Lewandrowski K., Shen J., Sahani D., Brugge W., Fernandez-del Castillo C. Pancreatic cysts: preoperative diagnosis and clinical management. Cancer Cytopathol 2010, 25:1-13.
27. Khalid A., Zahid M., Finkelstein S.D., LeBlanc J.K., Kaushik N., Ahmad N., et al. Pancreatic cysts fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest Endosc 2009, 69:1095-1102.
28. Travis W.D., Brambilla E., Noguchi M., Nicholson A., Geisinger K., Yatabe Y., et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285.
29. da Cunha Santos G., Saieg M.A., Geddie W., Leighl N. EGFR gene status in cytological samples of non small cell lung carcinoma: controversies and opportunities. Cancer Cytopathol 2011, 119:80-91.
30. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
31. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N Engl J Med 2010, 363:1693-1703.
32. Schmid S., Tinguely M., Cione P., Moch H., Bode B. Flow cytometry as an accurate tool to complement fine needle aspiration cytology in the diagnosis of low grade malignant lymphomas. Cytopathology 2011, 22:397-406.
33. Lazar A., Abruzzo L.V., Pollock R.E., Lee S., Czerniak B. Molecular diagnosis of sarcomas: chromosomal translocation in sarcomas. Arch Pathol Lab Med 2006, 130:1199-1208.
34. Klijanienko J., Couturier J., Bourdeaut F., Fréneaux P., Ballet S., Brisse H., et al. Fine-needle aspiration as a diagnostic technique in 50 cases of primary Ewing sarcoma/peripheral neuroectodermal tumor. Institut Curie's experience. Diagn Cytopathol 2012, 40:19-25.
35. Tanas M.R., Rubin B.P., Tubbs R.R., Billings S.D., Downs-Kelly E., Goldblum J.R., et al. Utilization of fluorescence in situ hybridization in the diagnosis of 230 mesenchymal neoplasms: an institutional experience. Arch Pathol Lab Med 2010, 134:1797-1803.
36. Al-Maghraby H.Q., Khalbuss W.E., Rao U.N., Cieply K., Dacic S., Monaco S.E. Fine needle aspiration biopsy diagnosis of dedifferentiated liposarcoma: cytomorphology and MDM2 amplification by FISH. Cytojournal 2010, 7:5.
37. Eszlinger M., Paschkea R. Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumour specific mutations and gene expression patterns. Mol Cell Endocr 2010, 322:29-37.
38. Nikiforov Y.E., Ohori N.P., Hodak S.P., Carty S.E., LeBeau S.O., Ferris R.L., et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011, 96:3390-3397.
39. Yip L., Kebebew E., Milas M., Carty S.E., Fahey T.J., Parangi S., et al. Summary statement: utility of molecular marker testing in thyroid cancer. Surgery 2010, 148:1313-1315.